10-Hydroxydecanoic acid
Based on 1 Customer Validation
10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells.
For research use only. We do not sell to patients.
- Purity : 99.77%
- CAS No.: 1679-53-4
- Formula: C10H20O3
- Molecular Weight:188.26
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-Y0148R
10-Hydroxydecanoic acid (Standard)Saturated Fatty Acid -
HY-N1363
Royal Jelly acidRoyal Jelly Fatty Acid -
HY-N0633
MusconeTNF Receptor Inhibitor -
HY-W008821
1,7-HeptanediamineDeoxyhypusine synthase Inhibitor -
HY-B0367
LornoxicamCOX Inhibitor -
HY-N8593
UndecanecAMP Agonist -
HY-N1363R
Royal Jelly acid (Standard)Royal Jelly Fatty Acid -
HY-N8593R
Undecane (Standard)Standard of Undecane -
HY-B0367R
Lornoxicam (Standard)COX Inhibitor -
HY-N0633R
Muscone (Standard)TNF Receptor Inhibitor
Biological Activity
Description
In Vitro
10-Hydroxydecanoic acid (0-10 mM; 30 min) inhibits LPS (HY-D1056)-induced NO production in RAW264 cells in a concentration-dependent manner within the range of 0.5-5 mM[1]. 10-Hydroxydecanoic acid (5 mM; 30 min) inhibits the increase of IRF-1 protein induced by LPS (HY-D1056) in RAW264 cells[1]. 10-Hydroxydecanoic acid (100 μM and 1 mM; 6 h) increases the expression level of RANK on the surface of caco2 cell monolayers[2]. 10-Hydroxydecanoic acid has a significant insecticidal effect on Aedes aegypti larvae (LC50=37.8 μg/mL)[3]. 10-Hydroxydecanoic acid has a significant anti-malarial effect (IC50=2.65μg/mL)[3]. 10-Hydroxydecanoic acid has a significant anti-Leishmania effect on intracellular amastigotes of Leishmania (IC50=3.77 μg/mL)[3]. 10-Hydroxydecanoic acid (0-4 mM; 1 h) effectively reduces the level of iNOS in BV-2 microglia induced by LPS (HY-D1056) and activates cell autophagy[4]. 10-Hydroxydecanoic acid (0-4 mM; 1 h) has no inhibitory effect on the increase of cyclooxygenase-2 (COX-2), iNOS and TNF-α induced by LPS in BV-2 microglia cells transfected with specific p53 siRNA[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-induced RAW264 cells
-
Concentration:0-10 mM
-
Incubation Time:30 min
-
Result:Inhibited the expression of iNOS mRNA.
Did not inhibit the increase of total IRF-1 mRNA level in cells after LPS stimulation, but reduced the IRF-1 mRNA level in polysomes at a dose of 5 mM.
-
Cell Line:LPS-induced RAW264 cells
-
Concentration:0-10 mM
-
Incubation Time:30 min
-
Result:Inhibited LPS-induced phosphorylation of Akt and eukaryotic initiation factor 4E-BP1.
-
Cell Line:LPS-induced BV-2 cells
-
Concentration:1, 2 and 4 mM
-
Incubation Time:1 h
-
Result:Inhibited the increase of IL-6, TNF, MCP-1, NLRP3, cleaved caspase-1 and IL-1β and reduced the level of p-p53 in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:cynomolgus macaque [2]
-
Dosage:1 mol/L, Administer 100 μL
-
Administration:Intranasal administration; once a day for 3 days
-
Result:Increased number of gp2-positive cells in the epithelium overlying NALT follicles.
-
Animal Model:cynomolgus macaque [2]
-
Dosage:2.4 mg
-
Administration:p.o.; enteric-coated capsules once a day for 20 days
-
Result:Increased the number of gp2-positive M cells.
10-HDAA (2.4 mg) enteric-coated capsules containing poliovirus antigen (106 TCID50) induced poliovirus- and influenza virus-specific IgAs on day 12 after oral administration.
Chemical Information
-
CAS No. 1679-53-4
-
Appearance Solid
-
Molecular Weight 188.26
-
Formula C10H20O3
-
Color White to off-white
-
SMILES
O=C(O)CCCCCCCCCO
-
Synonyms
NSC 15139; 10-HDAA
-
Structure Classification
-
Initial Source
major fatty acids in royal jelly
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (265.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (6.64 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (6.64 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Takahashi K, et al. Inhibitory effect of 10-hydroxydecanoic acid on lipopolysaccharide-induced nitric oxide production via translational downregulation of interferon regulatory factor-1 in RAW264 murine macrophages. Biomed Res. 2013 Aug;34(4):205-14. [Content Brief]
[2]. Isayama, et al. "10-Hydroxydecanoic acid potentially elicits antigen-specific IgA responses." Biological and Pharmaceutical Bulletin 43.8 (2020): 1202-1209. [Content Brief]
[3]. Alkhaibari, et al. Insecticidal, antimalarial, and antileishmanial effects of royal jelly and its three main fatty acids, trans‐10‐hydroxy‐2‐decenoic acid, 10‐hydroxydecanoic acid, and sebacic acid. Evidence‐Based Complementary and Alternative Medicine 2022.1 (2022): 7425322. [Content Brief]
[4]. Mengmeng, et al. "10-Hydroxydecanoic acid inhibits LPS-induced inflammation by targeting p53 in microglial cells." International Immunopharmacology 84 (2020): 106501. [Content Brief]
[5]. Mengmeng, et al. "Combined royal jelly 10-hydroxydecanoic acid and aspirin has a synergistic effect against memory deficit and neuroinflammation." Food & Function 13.4 (2022): 2336-2353. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.3118 mL | 26.5590 mL | 53.1180 mL | 132.7951 mL |
| 5 mM | 1.0624 mL | 5.3118 mL | 10.6236 mL | 26.5590 mL | |
| 10 mM | 0.5312 mL | 2.6559 mL | 5.3118 mL | 13.2795 mL | |
| 15 mM | 0.3541 mL | 1.7706 mL | 3.5412 mL | 8.8530 mL | |
| 20 mM | 0.2656 mL | 1.3280 mL | 2.6559 mL | 6.6398 mL | |
| 25 mM | 0.2125 mL | 1.0624 mL | 2.1247 mL | 5.3118 mL | |
| 30 mM | 0.1771 mL | 0.8853 mL | 1.7706 mL | 4.4265 mL | |
| 40 mM | 0.1328 mL | 0.6640 mL | 1.3280 mL | 3.3199 mL | |
| 50 mM | 0.1062 mL | 0.5312 mL | 1.0624 mL | 2.6559 mL | |
| 60 mM | 0.0885 mL | 0.4427 mL | 0.8853 mL | 2.2133 mL | |
| 80 mM | 0.0664 mL | 0.3320 mL | 0.6640 mL | 1.6599 mL | |
| 100 mM | 0.0531 mL | 0.2656 mL | 0.5312 mL | 1.3280 mL |
10-Hydroxydecanoic acid Related Classifications
HY-Y0148 Related Classifications
Powered by Bioz